The Pressana Occlusion Perfusion Catheter
®
Now Available: Next-Generation Universal Delivery Device for Therapeutic Agents
The patented Pressana Occlusion Perfusion Catheter (OPC) from Advanced Catheter Therapies (ACT) creates a localized treatment chamber for the targeted delivery of various types of physician-selected therapeutic agents for the treatment of different disease states.
-
Affords substantial procedural control
-
Controlled flushing, filling, circulation and evacuation of the treatment chamber through the inflow and outflow lumen
-
Measures pressure applied inside the treatment chamber
-
Demonstrated safety and efficacy
-
Cost effective based on FDA clearance to reposition device multiple times within the same patient to deliver multiple treatments
The only FDA liquid drug delivery technology cleared for below the knee use being actively marketed today
It's been said, "Save a limb, save a life." Each year, approximately 150,000 lower limb amputations are performed in the US with mortality rates at 1, 3 and 5 years reaching 15, 38, and 68%.* Maintaining good blood flow to the legs helps prevent amputations.
The Pressana OPC addresses peripheral arterial disease (PAD) and is adjunctive and complimentary to atherectomy, angioplasty and shockwave technologies by delivering agents post-vessel modification and/or debulking that prevent or slow restenosis. It is the only FDA drug delivery technology cleared for below the knee (BTK) use being actively marketed today. No drug-coated balloon has yet to be approved for BTK applications.
Pressana OPC enables direct endovascular delivery and infusion of various physician-prescribed therapeutic and diagnostic agents such as anticoagulants, antifibrins, antithrombins, anti-proliferatives, anti-
inflammatories, antineoplastics and limus drugs, or other agents used to treat occlusions, stenosis, thrombolysis and restenosis in the peripheral vasculature.
How it works:
-
Isolated perfusion chamber created by conforming distal and proximal occlusion balloons
-
Enhanced distribution and reduced agent volume provided by a center occupying balloon which is not intended to make contact with the arterial wall
-
Controlled flushing, filling, circulation and evacuation of the treatment chamber through the inflow and outflow lumen
-
Real-time monitoring of inter-arterial pressure within the perfusion chamber via fiberoptic sensor
-
Targeted delivery aided by radiopaque markers (x4)
*Molina CS, Faulk JB. Lower Extremity Amputation. [Updated 2020 Sep 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546594/
About Advanced Catheter Therapies
Pressana OPC technology was developed by Advanced Catheter Therapies, which was first funded in 2011. Ten years later, the company has raised $8.87 million, with only a small percentage being non-dilutive grants. Sales to date of the Pressana OPC total $7.8 million, including licensing fees. ACT's primary focus has been on R&D and licensing. The Pressana OPC has received three FDA 510(k) clearances and multiple patents.
Opportunities
-
Investors - participate in a Series C funding round to scale commercialization
-
Distributors - offer the Pressana OPC to your customers
-
Physicians - join KOLs like Cardiovascular Institute of the South in using the Pressana OPC for your patients
Contact us to learn more:
Paul J. Fitzpatrick, Chief Executive Officer, paul@acatheter.com
Potential Applications for the Pressana OPC
